Hewatele to inject Sh378m to double oxygen production as Covid fuels demand

Kenya's oxygen production firm Hewatele is doubling production this year to keep up with surging demand from hospitals that are treating critically ill Covid-19 patients, the company said.

Demand for the commodity has more than doubled to 880 tonnes from 410 tonnes before the pandemic, the ministry of health said, causing a steep shortage due to lack of installed capacity.

Kenya is confronting a severe fourth wave of Covid-19 infections that is putting pressure on health facilities.

"This country doesn't have capacity to put 2,000 patients under high flow oxygen at the same time. We need to do something urgently," said Bernard Olayo, founder of the company.

Hewatele plans to invest $3.5 million (Sh378 million) to double production to two tonnes a day by year-end, Mr Olayo said.

The firm produces oxygen by the chemical method, using a naturally occurring salt to separate nitrogen from the air.

"It (chemical method) has limitations because you can't produce a lot of oxygen," Mr Olayo said.

To resolve that issue, Hewatele will invest another $15 million (Sh1.62 billion) next year to build an air separation unit to produce liquid oxygen, which will lead to a ten-fold output increase to 20 tonnes per day, he said.

Kenya has only one such plant, which belongs to industrial gases firm BOC #ticker:BOC, said Mr Olayo, who was inspired to produce oxygen for hospitals by his experience as a young government doctor in the west of the country two decades ago.

"Children would die of pneumonia, not because we didn't know what to do, but because we didn't have oxygen," he said.

Hewatele's expansion is being financed by a combination of debt and equity from international financiers, he said.

But the process will not be easy since the pandemic has driven up demand for oxygen and for components used by oxygen plants.